**Reference list of all included studies**

1. Auliac JB, Chouaid C, Greillier L, et al. Randomized open-label non-comparative multicenter phase II trial of sequential erlotinib and docetaxel versus docetaxel alone in patients with non-small-cell lung cancer after failure of first-line chemotherapy: GFPC 10.02 study.[Erratum appears in Lung Cancer. 2015 Feb;87(2):210 Note: Greiller, L [corrected to Greillier, L]]. *Lung Cancer.*85(3):415-419.

2. Belvedere O, Follador A, Rossetto C, et al. A randomised phase II study of docetaxel/oxaliplatin and docetaxel in patients with previously treated non-small cell lung cancer: An Alpe-Adria Thoracic Oncology Multidisciplinary group trial (ATOM 019). *European Journal of Cancer.* 2011;47(11):1653-1659.

3. Bergqvist M, Holgersson G, Bondarenko I, et al. Phase II randomized study of the IGF-1R pathway modulator AXL1717 compared to docetaxel in patients with previously treated, locally advanced or metastatic non-small cell lung cancer. *Acta Oncologica.* 2017;56(3):441-447.

4. Blumenschein GR, Jr., Smit EF, Planchard D, et al. A randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC)+. *Annals of Oncology.* 2015;26(5):894-901.

5. Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. *New England Journal of Medicine.* 2015;373(17):1627-1639.

6. Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. *New England Journal of Medicine.* 2015;373(2):123-135.

7. Camps C, Massuti B, Jimenez A, et al. Randomized phase III study of 3-weekly versus weekly docetaxel in pretreated advanced non-small-cell lung cancer: a Spanish Lung Cancer Group trial. *Annals of Oncology.* 2005;17(3):467-472.

8. Chen YM, Shih JF, Perng RP, Tsai CM, Whang-Peng J. A randomized trial of different docetaxel schedules in non-small cell lung cancer patients who failed previous platinum-based chemotherapy. *Chest.* 2006;129(4):1031-1038.

9. Cortot AB, Audigier-Valette C, Molinier O, et al. Weekly paclitaxel plus bevacizumab versus docetaxel as second or third-line treatment in advanced non-squamous non-small cell lung cancer (NSCLC): Results from the phase III study IFCT-1103 ULTIMATE. *Journal of Clinical Oncology Conference.* 2016;34(Supplement 15).

10. Cufer T, Vrdoljak E, Gaafar R, Erensoy I, Pemberton K, Group SS. Phase II, open-label, randomized study (SIGN) of single-agent gefitinib (IRESSA) or docetaxel as second-line therapy in patients with advanced (stage IIIb or IV) non-small-cell lung cancer. *Anti-Cancer Drugs.* 2006;17(4):401-409.

11. Dong L, Han ZF, Feng ZH, Jia ZY. Comparison of pemetrexed and docetaxel as salvage chemotherapy for the treatment for nonsmall-cell lung cancer after the failure of epidermal growth factor receptor-tyrosine kinase inhibitors. *Journal of International Medical Research.* 2014;42(1):191-197.

12. Fehrenbacher L, Spira A, Ballinger M, et al. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. *Lancet.* 2016;387(10030):1837-1846.

13. Fossella FV, DeVore R, Kerr RN, et al. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group.[Erratum appears in J Clin Oncol. 2004 Jan 1;22(1):209]. *Journal of Clinical Oncology.*18(12):2354-2362.

14. Garon EB, Ciuleanu TE, Arrieta O, et al. Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): A multicentre, double-blind, randomised phase 3 trial. *The Lancet.* 2014;384(9944):665-673.

15. Gervais R, Ducolone A, Breton JL, et al. Phase II randomised trial comparing docetaxel given every 3 weeks with weekly schedule as second-line therapy in patients with advanced non-small-cell lung cancer (NSCLC). *Annals of Oncology.* 2005;16(1):90-96.

16. Gridelli C, Gallo C, Di Maio M, et al. A randomised clinical trial of two docetaxel regimens (weekly vs 3 week) in the second-line treatment of non-small-cell lung cancer. The DISTAL 01 study. *British Journal of Cancer.* 2004;91(12):1996-2004.

17. Hanna N, Juhasz E, Cainip C, et al. A randomized phase 2 trial of vintafolide and docetaxel in folate-receptor positive (FR+) advanced NSCLC patients: Final efficacy results. *Journal of Thoracic Oncology.* 2015;2):S173.

18. Hanna N, Shepherd FA, Fossella FV, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. *Journal of Clinical Oncology.* 2004;22(9):1589-1597.

19. Heist RS, Aren OR, Mita AC, et al. Randomized phase 2 trial of plinabulin (NPI-2358) plus docetaxel in patients with advanced non-small cell lung cancer (NSCLC). *Journal of Clinical Oncology Conference.* 2014;32(15 SUPPL. 1).

20. Herbst RS, Baas P, Kim DW, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): A randomised controlled trial. *The Lancet.* 2016;387(10027):1540-1550.

21. Herbst RS, Sun Y, Eberhardt WE, et al. Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial. *Lancet Oncology.* 2010;11(7):619-626.

22. Heymach JV, Johnson BE, Prager D, et al. Randomized, placebo-controlled phase II study of vandetanib plus docetaxel in previously treated non-small-cell lung cancer. *Journal of Clinical Oncology.* 2007;25(27):4270-4277.

23. Janne PA, Shaw AT, Pereira JR, et al. Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study. *Lancet Oncology.*2013;14(1):38-47.

24. Janne PA, Van Den Heuvel MM, Barlesi F, et al. Selumetinib plus docetaxel compared with docetaxel alone and progression-free survival in patients with KRAS-mutant advanced non-small cell lung cancer: The SELECT-1 randomized clinical trial. *JAMA - Journal of the American Medical Association.* 2017;317(18):1844-1853.

25. Jones S, Thompson D, Barton J, et al. A randomized phase II trial of oral topotecan versus docetaxel in the second-line treatment of non-small-cell lung cancer. *Clinical Lung Cancer.* 2008;9(3):154-159.

26. Kawaguchi T, Ando M, Asami K, et al. Randomized phase III trial of erlotinib versus docetaxel as second- or third-line therapy in patients with advanced non-small-cell lung cancer: Docetaxel and Erlotinib Lung Cancer Trial (DELTA). *Journal of Clinical Oncology.*2014;32(18):1902-1908.

27. Kim ES, Hirsh V, Mok T, et al. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. *Lancet.* 2008;372(9652):1809-1818.

28. Kim ES, Neubauer M, Cohn A, et al. Docetaxel or pemetrexed with or without cetuximab in recurrent or progressive non-small-cell lung cancer after platinum-based therapy: a phase 3, open-label, randomised trial.[Erratum appears in Lancet Oncol. 2014 Jan;15(1):e4]. *Lancet Oncology.* 2013;14(13):1326-1336.

29. Krzakowski M, Ramlau R, Jassem J, et al. Phase III trial comparing vinflunine with docetaxel in second-line advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy. *Journal of Clinical Oncology.* 2010;28(13):2167-2173.

30. Lai CL, Tsai CM, Chiu CH, et al. Phase II randomized trial of tri-weekly versus days 1 and 8 weekly docetaxel as a second-line treatment of advanced non-small cell lung cancer. *Japanese Journal of Clinical Oncology.* 2005;35(12):700-706.

31. Lee DH, Park K, Kim JH, et al. Randomized Phase III trial of gefitinib versus docetaxel in non-small cell lung cancer patients who have previously received platinum-based chemotherapy. *Clinical Cancer Research.* 2010;16(4):1307-1314.

32. Levy B, Spira A, Becker D, et al. A randomized, phase 2 trial of Docetaxel with or without PX-866, an irreversible oral phosphatidylinositol 3-kinase inhibitor, in patients with relapsed or metastatic non-small-cell lung cancer. *Journal of Thoracic Oncology: Official Publication of the International Association for the Study of Lung Cancer.* 2014;9(7):1031-1035.

33. Li R, Sun L, Wang J, Qian J, Wang Z, Jiao X. Pemetrexed versus docetaxel in second line non-small-cell lung cancer: results and subsets analyses of a multi-center, randomized, exploratory trial in Chinese patients. *Pulmonary Pharmacology & Therapeutics.* 2012;25(5):364-370.

34. Manegold C, Vansteenkiste J, Cardenal F, et al. Randomized phase II study of three doses of the integrin inhibitor cilengitide versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer. *Investigational New Drugs.* 2012;31(1):175-182.

35. Maruyama R, Nishiwaki Y, Tamura T, et al. Phase III study, V-15-32, of gefitinib versus docetaxel in previously treated Japanese patients with non-small-cell lung cancer. *Journal of Clinical Oncology.* 2008;26(26):4244-4252.

36. Murakami H, Yamanaka T, Seto T, et al. Phase II study of zoledronic acid combined with docetaxel for non-small-cell lung cancer: West Japan Oncology Group. *Cancer Science.* 2014;105(8):989-995.

37. Natale R, Blackhall F, Kowalski D, et al. Evaluation of antitumor activity using change in tumor size of the survivin antisense oligonucleotide LY2181308 in combination with docetaxel for second-line treatment of patients with non-small-cell lung cancer a randomized open-label phase II study a randomized open-label phase II study. *Journal of Thoracic Oncology.* 2014;9(11):1704-1708.

38. Nokihara H, Lu S, Mok TSK, et al. Randomized controlled trial of S-1 versus docetaxel in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy (East Asia S-1 Trial in Lung Cancer). *Annals of Oncology.* 2017;28(11):2698-2706.

39. Paz-Ares L, Ross H, O'Brien M, et al. Phase III trial comparing paclitaxel poliglumex vs docetaxel in the second-line treatment of non-small-cell lung cancer. *British Journal of Cancer.* 2008;98(10):1608-1613.

40. Pectasides D, Pectasides M, Farmakis D, et al. Comparison of docetaxel and docetaxel-irinotecan combination as second-line chemotherapy in advanced non-small-cell lung cancer: A randomized phase II trial. *Annals of Oncology.* 2005;16(2):294-299.

41. Pillai R, Fennell D, Kovcin V, et al. Phase 3 study of ganetespib, a heat shock protein 90 inhibitor, with docetaxel versus docetaxel in advanced non-small cell lung cancer (Galaxy-2). *Journal of Thoracic Oncology.* 2017;12 (1 Supplement 1):S7-S8.

42. Quoix E, Lebeau B, Depierre A, et al. Randomised, multicentre phase II study assessing two doses of docetaxel (75 or 100 mg/m2) as second-line monotherapy for non-small-cell lung cancer. *Annals of Oncology.* 2004;15(1):38-44.

43. Ramalingam S, Goss G, Rosell R, et al. A randomized phase II study of ganetespib, a heat shock protein 90 inhibitor, in combination with docetaxel in second-line therapy of advanced non-small cell lung cancer (GALAXY-1). *Annals of Oncology.* 2015;26(8):1741-1748.

44. Ramlau R, Gervais R, Krzakowski M, et al. Phase III study comparing oral topotecan to intravenous docetaxel in patients with pretreated advanced non-small-cell lung cancer. *Journal of Clinical Oncology.* 2006;24(18):2800-2807.

45. Ramlau R, Gorbunova V, Ciuleanu TE, et al. Aflibercept and docetaxel versus docetaxel alone after platinum failure in patients with advanced or metastatic non-small-cell lung cancer: A randomized, controlled phase III trial. *Journal of Clinical Oncology.* 2012;30(29):3640-3647.

46. Ready N, Karaseva NA, Orlov SV, et al. Double-blind, placebo-controlled, randomized phase 2 study of the proapoptotic agent AT-101 plus docetaxel, in second-line non-small cell lung cancer. *Journal of Thoracic Oncology: Official Publication of the International Association for the Study of Lung Cancer.* 2011;6(4):781-785.

47. Reck M, Kaiser R, Mellemgaard A, et al. Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial. *Lancet Oncology.* 2014;15(2):143-155.

48. Rittmeyer A, Barlesi F, Waterkamp D, et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. *The Lancet.* 2017;389(10066):255-265.

49. Schuette W, Nagel S, Blankenburg T, et al. Phase III study of second-line chemotherapy for advanced non-small-cell lung cancer with weekly compared with 3-weekly docetaxel. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology.* 2005;23(33):8389-8395.

50. Segawa Y, Kiura K, Hotta K, et al. A randomized phase II study of a combination of docetaxel and S-1 versus docetaxel monotherapy in patients with non-small cell lung cancer previously treated with platinum-based chemotherapy: results of Okayama Lung Cancer Study Group (OLCSG) Trial 0503. *Journal of Thoracic Oncology: Official Publication of the International Association for the Study of Lung Cancer.* 2010;5(9):1430-1434.

51. Shaw AT, Kim DW, Nakagawa K, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.[Erratum appears in N Engl J Med. 2015 Oct 15;373(16):1582; PMID: 26466010]. *New England Journal of Medicine.* 2013;368(25):2385-2394.

52. Shepherd FA, Dancey J, Ramlau R, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. *Journal of Clinical Oncology.* 2000;18(10):2095-2103.

53. Soria JC, Fulop A, Maciel C, et al. SELECT-2: A phase II, double-blind, randomized, placebo-controlled study to assess the efficacy of selumetinib plus docetaxel as a second-line treatment of patients with advanced or metastatic non-small-cell lung cancer. *Annals of Oncology.* 2017;28(12):3028-3036.

54. Spigel DR, Bondarenko I, Losonczy G, et al. Top-line results from SUNRISE: A phase III, randomized, double-blind, placebo-controlled multicenter trial of bavituximab plus docetaxel in patients with previously treated stage IIIb/iv non-squamous non-small cell lung cancer. *Annals of Oncology Conference: 41st European Society for Medical Oncology Congress, ESMO.* 2016;27(Supplement 6).

55. Sun Y, Wu YL, Zhou CC, et al. Second-line pemetrexed versus docetaxel in Chinese patients with locally advanced or metastatic non-small cell lung cancer: a randomized, open-label study. *Lung Cancer.* 2013;79(2):143-150.

56. Takayama K, Sugawara S, Saijo Y, et al. Randomized Phase II Study of Docetaxel plus Personalized Peptide Vaccination versus Docetaxel plus Placebo for Patients with Previously Treated Advanced Wild Type EGFR Non-Small-Cell Lung Cancer. *Journal of Immunology Research.* 2016;2016 (no pagination)(1745108).

57. Takeda K, Negoro S, Tamura T, et al. Phase III trial of docetaxel plus gemcitabine versus docetaxel in second-line treatment for non-small-cell lung cancer: results of a Japan Clinical Oncology Group trial (JCOG0104). *Annals of Oncology.* 2016;20(5):835-841.

58. Takeda M, Yamanaka T, Seto T, et al. Bevacizumab beyond disease progression after first-line treatment with bevacizumab plus chemotherapy in advanced nonsquamous non-small cell lung cancer (West Japan Oncology Group 5910L): An open-label, randomized, phase 2 trial. *Cancer.* 2016;122(7):1050-1059.

59. Vergnenegre A, Corre R, Berard H, et al. Cost-effectiveness of second-line chemotherapy for non-small cell lung cancer: an economic, randomized, prospective, multicenter phase III trial comparing docetaxel and pemetrexed: the GFPC 05-06 study. *Journal of Thoracic Oncology: Official Publication of the International Association for the Study of Lung Cancer.* 2011;6(1):161-168.

60. Wachters FM, Groen HJ, Biesma B, et al. A randomised phase II trial of docetaxel vs docetaxel and irinotecan in patients with stage IIIb-IV non-small-cell lung cancer who failed first-line treatment. *British Journal of Cancer.* 2005;92(1):15-20.

61. Wen S, Fu X, Li G, et al. Efficacy of tamoxifen in combination with docetaxel in patients with advanced non-small-cell lung cancer pretreated with platinum-based chemotherapy. *Anti-Cancer Drugs.* 2016;27(5):447-456.

62. Yoh K, Hosomi Y, Kasahara K, et al. A randomized, double-blind, phase II study of ramucirumab plus docetaxel vs placebo plus docetaxel in Japanese patients with stage IV non-small cell lung cancer after disease progression on platinum-based therapy. *Lung Cancer.* 2016;99:186-193.

63. Yoshioka H, Katakami N, Okamoto H, et al. A randomized, open-label, phase III trial comparing amrubicin versus docetaxel in patients with previously treated non-small-cell lung cancer. *Annals of Oncology.* 2017;28(2):285-291.